News Xlife Sciences AG

Equities

XLS

CH0461929603

Market Closed - Swiss Exchange Other stock markets 09:01:19 06/05/2024 pm IST			5-day change	1st Jan Change
34.5 ^CHF	+2.99%		+4.86%	-30.86%

23/04	Xlife Sciences Posts Higher FY23 Profit; Revenue Falls	MT
29/02	Xlife Sciences AG Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Xlife Sciences : Valuation Report 2023	30/04	PU
Xlife Sciences AG Reports Strong Portfolio Growth and Strategic Advances in the 2023 Valuation Report	30/04	EQ
Xlife Sciences Posts Higher FY23 Profit; Revenue Falls	23/04	MT
Xlife Sciences AG Publishes 2023 Annual Report	23/04	EQ
Xlife Sciences AG Announces Collaboration Agreement Between its Portfolio Company FUSE-AI GmbH and T-Systems Switzerland	03/04	EQ
Xlife Sciences AG Reports Earnings Results for the Full Year Ended December 31, 2023	29/02	CI
Switzerland’s Xlife Sciences, Abu Dhabi Expand Existing Life Sciences Partnership	05/02	MT
Xlife Sciences AG Expands Collaboration with Department of Health Abu Dhabi, Partners with Thermo Fisher Scientific and Masdar City	05/02	EQ
VERAXA Biotech AG acquires Synimmune GmbH to expand cancer pipeline	29/12	EQ
Xlife Sciences AG Achieves Significant Milestone in the Development of Radiodiagnostics for Liver Diseases	22/12	EQ
Xlife Sciences, Quant Team Up to Develop Biomarkers for Kidney Diseases Detection	20/12	MT
Xlife Sciences AG paves the way for the next successful out-licensing and announces cooperation with Quant Biomarkers AG for the development of advanced biomarkers for kidney diseases	20/12	EQ
Revolutionary AI Algorithm «Prostate.Carcinoma.ai» Achieves EU MDR Class IIa Registration	18/12	EQ
Xlife Sciences to Sell Portfolio Company to 4D Lifetec	18/23/18	MT
Successful exit of portfolio company and major invest in AI and digital health in early cancer detection, valued at CHF 23.3 million	18/23/18	EQ
Xlife Sciences AG acquired 20% stake in 4D Lifetec AG for CHF 23.3 million.	18/23/18	CI
ESG Report shows status quo and outlines path for future sustainability improvements Media Release Zurich, September 29, 2023	29/23/29	EQ
Xlife Sciences Loss Narrows in H1; Revenue Declines	21/23/21	MT
Xlife Sciences with significant progress in H1 2023	21/23/21	EQ
Xlife Sciences AG Reports Earnings Results for the Half Year Ended June 30, 2023	21/23/21	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Xlife Sciences AG

Equities

XLS

CH0461929603

Summary

Filters